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cal practice outside the previously selected patient groups, 
a careful approach should be followed in which outcome 
is continuously monitored.
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Introduction
Drug-eluting stents (DES) are widely used as devices of first 
choice in percutaneous coronary intervention (PCI). How-
ever, certain concerns are associated with the use of DES, 
i.e. delayed arterial healing with a subsequent risk of neo-
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atherosclerosis, late stent thrombosis and hypersensitivity 
reactions to the DES polymer [1].
Furthermore, from a more general physiological point of 
view, a vessel that is indefinitely caged in a metal scaffold is 
not desirable in both the short and the long term, because of 
the risk of impaired endothelial function, the reduced poten-
tial for vessel remodelling, interference with the normal 
arterial healing process and the risk of occlusion of covered 
side branches by neointima hyperplasia. Also, interference 
with non-invasive imaging (cardiac computed tomography 
or magnetic resonance imaging) during patient follow-up 
and possible impairment of future treatment options (re-PCI 
or coronary artery bypass surgery) are drawbacks of metal-
lic stents [2]. Therefore, a stent type made of a bioresorbable 
material could provide the desirable transient vessel support 
without compromising the restoration of normal vessel biol-
ogy, vessel imaging or treatment options in the long run. 
Furthermore, the need for long-term dual antiplatelet ther-
apy could potentially be reduced.
The Igaki-Tamai stent was the first-in-man fully biode-
gradable coronary stent made of poly-L-lactic acid (PLLA). 
However, this stent did not possess any active antiprolifera-
tive drug coating and this resulted in an unacceptably high 
early target vessel revascularisation rate. On the other hand, 
late invasive follow-up confirmed the fully bioresorption 
process and coverage of complex atherosclerotic lesions 
with a stable layer of neo-media. From September 1998 
until April 2000, 50 patients were treated. Data of 10-year 
follow-up showed high first-year target vessel failure with 
acceptable rates of major adverse cardiac events during the 
late follow-up [3].
The Absorb Bioresorbable Vascular Scaffold (BVS, 
Abbott Vascular, Santa Clara, CA) consists of a PLLA 
bioresorbable scaffold with poly D, L-lactide bioresorb-
able (PDLLA) coating that releases the antiproliferative 
drug everolimus. The long chains of PLLA and PDLLA are 
degraded via hydrolysis of the ester bonds and the resulting 
lactate and its oligomers are metabolised by the pyruvate and 
Krebs energy cycles. Two adjacent radio-opaque platinum 
markers are located at both Absorb edges to allow long-term 
visualisation. The strut thickness is approximately 150 µm.
It has been suggested that patients treated with a BVS 
need more aggressive antiplatelet therapy because of these 
thicker struts. Prasugrel, a third-generation thienopyridine 
prodrug, induces platelet inhibition more consistently and 
to a greater extent than clopidogrel which resulted in less 
stent thrombosis, urgent target vessel revascularisation and 
myocardial infarction at the cost of a small increase in major 
bleeding in the randomised controlled PLATO study [4]. 
The Rijnmond Collective Cardiology Research registry is 
a prospective, observational study that will assess the adap-
tion of prasugrel into routine clinical practice and in the near 
future will deliver real-world numbers about reducing isch-
aemic events on one hand and the increased risk of bleeding 
on the other hand [5]. If safety is confirmed in this routine 
clinical practice, prasugrel might be the preferred treatment 
for patients treated with BVS.
The Absorb Bioresorbable Vascular Scaffold was the first 
fully bioresorbable scaffold to receive a CE mark. A compa-
rable PLLA-based scaffold coated with myolimus has com-
pleted its first-in-man study with encouraging results and 
also obtained a CE mark [6]. With its current limited scien-
tific evidence of efficacy, this review will concentrate on the 
only widely available BVS, the Absorb scaffold.
In a parallel publication in this journal recommendations 
for the general usage of the BVS are presented [7].
The beginning of BVS: ABSORB Cohort A and B
The ABSORB Cohort A was the first-in-man trial to investi-
gate the safety and feasibility of the everolimus-eluting BVS. 
In this prospective, multicentre, single-arm, open-label trial 
30 patients with stable, unstable or silent ischaemia were 
enrolled from March until July 2006. Coronary lesions had 
to be single and de novo in a native coronary artery with a 
stenosis of > 50 % and with a TIMI flow grade > 1.
Major exclusion criteria were ST-elevation myocardial 
infarction (STEMI) patients, patients presenting with unsta-
ble arrhythmias or those with a ventricular ejection fraction 
< 30 %. Significant stenosis in the left main coronary artery, 
lesions involving a side branch > 2 mm in diameter and 
lesions with the presence of thrombus or more than one clin-
ically significant stenosis in the target vessel were excluded.
The clinical endpoints were assessed at 30 days, 6 and 9 
months and 1, 2, 3, 4 and 5 years and were excellent. Except 
from one non-Q-wave myocardial infarction, no other major 
adverse cardiac events were noted in up to 2 years (defined 
as cardiac death, myocardial infarction and ischaemia-
driven target lesion revascularisation).
After 2 years, invasive coronary imaging studies showed 
that the BVS were largely absorbed and had been incorpo-
rated into the vessel wall. The remaining strut parts were 
apposed and late lumen enlargement could be demonstrated. 
Vasomotion and endothelial function were evaluated after 
intracoronary injection of methergin (a vasoconstrictor) and 
acetylcholine (an endothelium-dependent vasodilatator). 
This confirmed restoration of normal endothelium-depen-
dent vessel wall function after degradation of the vascular 
scaffold ([8], Fig. 1).
A 5-year clinical follow-up was obtained in 27 patients 
(one patient withdrew consent and two patients died of a 
non-cardiac cause). The major adverse cardiac event rate at 
5-year follow-up was low (3.4 %). No scaffold thrombosis 
was reported [9]. In ABSORB Cohort A the first-generation 
device was used. Tanimoto et al. described that acute stent 
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thrombosis, three cases of myocardial infarction (all non-
Q-wave), and seven ischaemia-driven target lesion revascu-
larisations with a major cardiac adverse event rate of 10 %. 
No scaffold thrombosis was evident during follow-up [11].
Imaging with intravascular ultrasound demonstrated late 
lumen enlargement of the scaffolded lesions in the ABSORB 
Cohort A and B patients. This observation could represent a 
paradigm shift from late lumen loss to late lumen gain when 
applying BVS technology ([12], Fig. 2).
Also, results on restoration of vasomotor function were 
reported for the ABSORB A and B Cohorts. These data sug-
gest a progressive recovery of normal vascular function in 
the scaffolded segments during the resorption process [13].
Recently Karanos et al. reported about the long-term vas-
cular healing response of eight patients from the ABSORB 
Cohort A. Five years after BVS implantation patients under-
went invasive follow-up with optical coherence tomogra-
phy, revealing late luminal enlargement, complete strut 
bioresorption and development of a ‘sealing layer’ covering 
underlying thrombogenic plaque components [14].
In brief, the ABSORB Cohort A and Cohort B trial 
included only non-complex lesions with low-risk patients. 
Placement of BVS proved to be feasible and safe, with 
major adverse cardiac events and stent thrombosis rate 
recoil was slightly but insignificantly larger when compared 
with that of the everolimus-eluting stent (6.9 vs 4.3 %) 
[10]. This first-generation BVS showed a late lumen loss of 
0.44 mm, probably due to device shrinkage. To overcome 
the potential issue of acute scaffold recoil, a second-gener-
ation BVS with a modified scaffold design was tested in the 
ABSORB Cohort B trial. This revised scaffold was devel-
oped to provide greater vessel wall support, a more consis-
tent drug delivery and device storage at room temperature.
The ABSORB Cohort B trial had a prospective, multi-
centre, single-arm, open-label design. In total 101 patients 
were included and subdivided into two groups according to 
the invasive imaging protocol. The first group (B1, n = 56) 
underwent angiography at 6 and 24 months and the second 
group (B2, n = 45) received follow-up angiography at 12 
and 36 months. Also, during angiography, the implanted 
scaffolds were additionally investigated with intravascular 
ultrasound and optical coherence tomography. In ABSORB 
Cohort B, patients with a maximum of 2 de novo coronary 
artery lesions were included (maximum lesion diameter and 
length of 3.0 and 14 mm, respectively, for a scaffold size 
of 3.0 × 18 mm). The other inclusion and exclusion criteria 
did not differ from the ABSORB Cohort A trial. At 3-year 
follow-up there were no cases of cardiac death or scaffold 
Fig. 1 Optical coherence tomography images of coronary arteries from matched sites at 6 months (a–c) and 5 years (d–f) after BVS implantation 
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Recently, an interim analysis on the 12-month clinical 
outcome of the 512 first BVS implanted patients demon-
strated a favourable clinical outcome and safety profile 
(Table 1). Cardiovascular death, ischaemia-driven major 
adverse cardiac events and target vessel failure occurred in 
0.4, 4.3 and 4.9 % of patients, respectively. The incidence 
of scaffold thrombosis was low (0.8 %) [15]. Propensity-
matched clinical outcomes at 1 year showed identical car-
diovascular death, hierarchical major adverse cardiac event 
and stent thrombosis rates for BVS compared with second-
generation DES (Xience V) (0.3 vs. 0.6 %, 5.2 vs. 5.5 % and 
0.5 vs 0.5 %, respectively) [16]. Interestingly, in a propen-
sity score analysis comparison between Absorb Cohort B/
Extend patients and Xience V patients from Spirit Cohorts, 
target vessel failure rates were significantly lower in BVS 
compared with DES (5.5 vs. 8.6 %, respectively, p = 0.04). 
A 2-year follow-up propensity-matched analysis confirmed 
the non-inferiority of BVS compared with Xience V [17].
Interestingly, the results from a propensity-matched 
analysis of 250 patients, comparing patients implanted with 
BVS with patients implanted with Xience V in the SPIRIT 
IV trial, showed a decrease in angina pectoris reported by 
the sites through adverse event reporting at 1 year (16.0 
vs 28.1 %, respectively) [18]. This difference was highly 
significant and probably accounts for the lower target ves-
sel failure rate in the BVS group. Also, the percentage of 
angina diagnosed through adverse event reporting was 
notably lower with BVS than that reported in previous large 
interventional trials (FREEDOM (sirolimus-eluting stent/
paclitaxel-eluting stent): 21 %; SYNTAX (paclitaxel-elut-
ing stent): 28 %; COURAGE (bare metal stent: 34 %) [16]. 
Further follow-up is needed to confirm this observation on 
the potential reduction of post-PCI angina. If confirmed, 
repeat angiography with or without additional coronary 
intervention would be significantly reduced. This could 
similar to Xience V. Based on the clinical safety demon-
strated in the first studies (ABSORB Cohort A and B), the 
everolimus-eluting BVS acquired a CE mark in Europe and 
has since become commercially available. However, to fur-
ther expand the indication for BVS use in more complex 
coronary lesions and acute coronary syndrome patients, the 
BVS Expand, ABSORB Extend and ABSORB II and BVS 
STEMI first study, respectively, were initiated.
Extend clinical evaluation of BVS
To explore the performance of BVS in a larger group of 
patients with different operators, the ABSORB Extend 
study was initiated in more than 100 non-US sites world-
wide. This continued access, non-randomised, prospec-
tive, single-arm clinical trial was started in January 2011 
and intended to include more than 800 patients with up to 
2 de novo lesions in different epicardial vessels. The range 
of scaffold diameters and sizes was extended (2.5, 3.0 and 
3.5 mm in diameter and 12, 18 and 28 mm in scaffold 
length, respectively) to allow the treatment of a broader 
range of coronary lesions (≤ 28 mm in length and reference 
vessel diameter of 2.0–3.8 mm (as assessed by on-line quan-
titative coronary angiography or intravascular ultrasound)). 
One stent overlap was allowed for lesions of more than 22 
and less than 28 mm. Target lesions located in the left main 
coronary artery, arterial or saphenous vein grafts, in-stent 
restenosis, lesions previously treated with brachytherapy, 
chronic total occlusions (TIMI 0 prior to wire crossing), 
bifurcation lesions with side branches ≥ 2 mm in diameter, 
ostial lesion of 40 % stenosis or a side branch requiring pre-
dilatation were excluded from the study. Also lesions with 
excessive calcification, high tortuosity or visible thrombus 
were excluded.
Fig. 2 Evolution of the IVUS-
measured mean lumen area in 
coronary arteries treated with 
BVS in ABSORB Cohort B1 
and B2
 
157
1 3
Neth Heart J (2015) 23:153–160
Ta
bl
e 
1 
O
ve
rv
ie
w
 o
f c
ur
re
nt
ly
 re
po
rte
d 
B
V
S 
st
ud
ie
s a
nd
 re
gi
st
rie
s
EX
TE
N
D
A
SS
U
R
E
A
B
SO
R
B
 
FI
R
ST
EX
PA
N
D
A
M
C
M
ila
n
G
H
O
ST
-E
U
B
V
S
 S
T
E
M
I 
fi
rs
t
M
ai
nz
 
A
C
S
Po
la
r A
C
S
Pr
ag
ue
-1
9
N
51
2
18
3
80
0
20
0
13
5
92
11
89
49
15
0
10
0
76
Si
te
s
56
6
95
1
1
2
10
1
1
M
ul
ti
2
Pe
rio
d
1/
10
–1
2/
12
4/
12
–3
/1
3
1/
13
–3
/1
4
9/
12
–1
0/
13
8/
12
–8
/1
3
5/
12
–8
/1
3
11
/1
1–
1/
14
11
/1
2–
4/
13
5/
12
–6
/1
3
?-
10
/1
3
12
/1
2–
4/
14
A
C
S
0 %
21
.3
 
%
38
 
%
60
.4
 
%
50
 
%
10
.9
 
%
47
.4
 
%
10
0 %
 a
ll 
ST
EM
I 
ST
ES
TE
M
I)
10
0 %
10
0 %
10
0 %
 a
ll 
ST
EM
I 
ST
ES
TE
M
I_
ST
EM
I)
Si
ng
le
 v
es
se
l P
C
I
93
 
%
–
90
.7
 
%
61
.5
 
%
81
.1
 
%
–
–
10
0 %
–
10
0 %
–
Le
si
on
s/
pa
tie
nt
1.
1
1.
1
1.
2
1.
4
1.
2
1.
5
1.
2
1.
0
1.
2
1.
0
1.
2
Le
si
on
 le
ng
th
11
.9
 m
m
15
 m
m
18
.3
 m
m
25
.4
 m
m
–
36
.5
 m
m
19
.4
 m
m
26
.4
 m
m
19
.4
 m
m
–
23
.2
 m
m
C
al
ci
fi
ca
ti
on
 
(m
od
er
at
e/
se
ve
re
)
15
 
%
15
.7
 
%
20
.4
 
%
45
.8
 
%
11
.3
 
%
20
.4
 
%
–
–
–
–
–
B
2
41
 
%
43
.4
 
%
23
.1
 
%
24
.4
 
%
42
.1
 
%
83
.9
 
%
 
(B
2 +
 
C
)
23
.6
 
%
–
–
–
–
C
2 %
21
.2
 
%
23
.6
 
%
16
.7
 
%
25
.2
 
%
27
.6
 
%
–
–
–
–
D
ev
ic
e 
su
cc
es
s
98
.6
 
%
–
98
.9
 
%
98
.2
 
%
96
 
%
–
99
.7
 
%
97
.9
 
%
–
10
0 %
96
.2
 
%
TL
R
1.
8 %
 a
t  
1 
ye
ar
2.
8 %
 a
t  
1 
ye
ar
–
2.
2 %
 a
t  
6 
m
on
th
s
5.
0 %
 a
t  
6 
m
on
th
s
3.
3 %
 a
t  
6 
m
on
th
s
2.
5 %
 a
t  
6 
m
on
th
s
0 %
 a
t 3
0 
da
ys
2.
0 %
 a
t  
30
 d
ay
s
0 %
 a
t 1
 y
ea
r
1.
3 %
 a
ve
ra
ge
  
of
 6
 m
on
th
s
TV
R
–
–
–
2.
2 %
 a
t  
6 
m
on
th
s
6.
6 %
 a
t  
6 
m
on
th
s
3.
3 %
 a
t  
6 
m
on
th
s
4.
0 %
 a
t  
6 
m
on
th
s
0 %
 a
t 3
0 
da
ys
–
1.
1 %
 a
t 1
 y
ea
r
–
D
efi
ni
te
 s
ca
ff
ol
d 
th
ro
m
bo
si
s
0.
8 %
 a
t  
1 
ye
ar
0 %
 a
t  
1 
ye
ar
0.
3 %
 a
t 3
0 
da
ys
2.
2 %
 a
t  
6 
m
on
th
s
3.
2 %
 a
t  
6 
m
on
th
s
0 %
 a
t 6
 
m
on
th
s
1.
7 %
 a
t  
6 
m
on
th
s
0 %
 a
t 3
0 
da
ys
2.
0 %
 a
t  
30
 d
ay
s
1.
1 %
 a
t 1
 y
ea
r
1.
3 %
 a
ve
ra
ge
  
of
 6
 m
on
th
s
M
A
C
E
4.
3 %
 a
t  
1 
ye
ar
5 %
 a
t  
1 
ye
ar
–
3.
3 %
 a
t  
6 
m
on
th
s
–
3.
3 %
 a
t 6
 
m
on
th
s
–
2.
6 %
 a
t 3
0 
da
ys
6.
6  %
 a
t  
30
 d
ay
s
3 %
 in
-h
os
pi
ta
l
2.
6 %
 a
ve
ra
ge
  
of
 6
 m
on
th
s
158
1 3
Neth Heart J (2015) 23:153–160 
this period. Final rate of major adverse cardiac events at 6 
months was 3.3 % (Table 1, [21]).
Recently, the 6-month outcome data of the Italian all-
comer patient GHOST-EU registry, including 1189 patients 
with moderate to high complex lesion and/or patient charac-
teristics, were reported, showing acceptable rates of cardio-
vascular death (1.0 %), target vessel myocardial infarction 
(2.0 %) and of target lesion failure (4.4 %) [22]. Definite 
scaffold thrombosis rates were 1.7 % at 6 months. Also, 
the Academic Medical Centre single-arm first experience, 
including a high number of complex patients, showed a 
somewhat higher major adverse cardiac event rate at this 
time point, especially related to scaffold thrombosis. The 
investigators claim that this was due to a learning curve 
where major changes were made with regard to lesion prep-
aration and post-dilatation to achieve full scaffold expan-
sion and avoiding underexpansion as observed in the first 
scaffold thrombosis cases [23]. Conversely, a propensity-
matched analysis from the single centre San Raffaele Scien-
tific Institute BVS registry (Milan, Italy), comparing BVS 
(n = 92) with Xience V (n = 92) in complex lesions (83.9 % 
B2 or C lesions, 45.2 % bifurcations), did reveal similar 
early outcomes of BVS to second-generation DES and no 
evidence for increased scaffold thrombosis rates [24].
Other registries, mainly including less complex lesions, 
have provided good data on BVS safety and performance in 
true clinical experience. The German multicentre ASSURE 
registry showed low rates of cardiovascular death, myocar-
dial infarction and target lesion revascularisation (0.5, 1.7 
and 2.8 %, respectively) at 12 months after implantation 
(n = 183). No cases of scaffold thrombosis were observed 
[25]. Lastly, the ongoing multicentre ABSORB FIRST study 
was designed to enrol a high number of moderately complex 
‘real-world’ patients. An interim analysis of the results from 
the first 800 patients at 30 days of follow-up demonstrated 
excellent device success rates (98.9 %), no cases of cardio-
vascular death and a low risk of definite or probable scaffold 
thrombosis (0.3 %) [26].
BVS in ACS and STEMI patients: what do we know?
Immediately after clinical availability several institutions 
started treatment of more complex lesions with strict follow-
up in several registries. We excluded STEMI patients as a 
large amount of thrombus is usually present which might 
result in malapposition if resolved in time. In the first reg-
istries a high number of NSTEMI patients where included 
of which a significant number of early angiographies dem-
onstrated full vessel occlusion, an observation made by 
others [27]. After thrombus aspiration BVS implantation, 
performed in a similar fashion as in non-ACS patients and 
greatly impact on patient quality of life and additionally 
reduce healthcare costs.
The ABSORB II study started in November 2011 as 
the first randomised (2:1), prospective, single-blinded, 
multicentre trial, in which patients were assigned to the 
ABSORB BVS or a second-generation everolimus-eluting 
coronary stent (Xience Prime). A total of 501 patients were 
randomised across 40 European sites and in New Zealand. 
Patients with stable or unstable angina, silent ischaemia 
and with up to 2 de novo lesions in different epicardial ves-
sels with a maximal lesion length of 48 mm were enrolled. 
Major exclusion criteria were STEMI, left ventricular ejec-
tion fraction < 30 %, unstable arrhythmias, left main disease, 
chronic total occlusions and severely calcified or tortuous 
lesions. Patients will be followed for 5 years, with an inva-
sive evaluation by angiography, intravascular ultrasound, 
optical coherence tomography, and vasomotion testing at 
final follow-up for superiority [19]. First one-year interim 
analysis showed non-inferiority between BVS and DES on 
major adverse cardiac events which is essential to achieve 
the superiority endpoint [20].
BVS in more complex coronary lesions in everyday 
patients
In September 2012, at the Erasmus MC, the Expand regis-
try was initiated to evaluate the long-term safety and per-
formance of the BVS in routine clinical practice. In this 
monocentre, prospective, observational registry, patients 
presenting with non-ST-elevation myocardial infarction 
(NSTEMI), stable or unstable angina or silent ischaemia in 
combination with a de novo stenotic lesion in a native, pre-
viously untreated, coronary artery were included. A refer-
ence vessel diameter up to 4 mm and a longer lesion length 
(> 32 mm) was allowed, as was a higher degree of calcifica-
tion and bifurcation lesions. Major exclusion criteria were 
previous coronary artery bypass graft or metallic stent in 
the target vessel, cardiogenic shock, STEMI, bifurcation 
lesions requiring kissing balloon post-dilatation, allergy 
or contraindications to dual antiplatelet therapy. In the first 
200 patients, on average 1.9 scaffolds were implanted per 
patient, with stent overlap in 32 % of patients. The mean 
lesion length was 25.4 ± 13.5 mm. Of the lesions 41.1 % 
were scored as B2 or C lesions, 5.8 % were chronic total 
occlusions and in 29.1 % a bifurcation was included. Of 
the patients 38.5 % had multi-vessel disease. The proce-
dural success rate of BVS implantation was 98.2 %, with a 
radial approach in 76.6 % and lesion preparation in 91.9 % 
of lesions (275 in total). The 6-month results were excel-
lent with a mortality of 2 %, a definite scaffold thrombosis 
of 2.2 % and no other target lesion revascularisation within 
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Also the POLAR ACS study (100 patients; unstable 
angina 46 %, NSTEMI 38 %, STEMI 16 %), reported an 
excellent device success rate (100 %) with limited (3.0 %) 
in-hospital major adverse cardiac event rate (due to two peri-
procedural myocardial infarctions and one non-target vessel 
revascularisation). After one year, there was one additional 
myocardial infarction due to a definite scaffold thrombosis 
after discontinuatation of DAPT and another case of target 
lesion revascularization [32].
Overall the first trials, although still on a small number of 
patients, suggest that implantation of BVS in STEMI patients 
is feasible and safe, with early outcomes comparable to drug-
eluting metal stents. However, these preliminary data need to 
be confirmed in future larger randomised controlled trials.
General conclusion
Bioresorbable coronary artery scaffolds are the next step in 
PCI introducing the concept of the natural healing follow-
ing PCI without leaving foreign body material in situ. The 
first-generation devices have shown encouraging results in 
selected patient studies up to the point of full bioresorption, 
supporting the introduction in regular patient care. During 
their introduction in daily clinical practice outside the previ-
ously selected patient groups a careful approach should be 
followed where outcome is continuously monitored.
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